By Colin Kellaher
Johnson & Johnson’s Janssen Pharmaceutical Cos. unit on Monday said the European Commission approved expanded use of its Spravato nasal spray for the rapid reduction of depressive symptoms in a psychiatric emergency for adults with major depressive disorder.
The drug maker said the approval covers Spravato, co-administered with oral antidepressant therapy, as an acute short-term treatment for the rapid reduction of depressive symptoms that, according to clinical judgment, constitute a psychiatric emergency.
The European Commission previously approved Spravato for adults with treatment-resistant major depressive disorder.
Write to Colin Kellaher at colin.kellaher@Fintech Zoom.com
(END) Dow Jones Newswires